Range Financial Group LLC Has $2.08 Million Stock Position in Novo Nordisk A/S $NVO

Range Financial Group LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 226.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,511 shares of the company’s stock after acquiring an additional 26,020 shares during the period. Range Financial Group LLC’s holdings in Novo Nordisk A/S were worth $2,081,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Encompass More Asset Management raised its holdings in Novo Nordisk A/S by 27.6% during the 3rd quarter. Encompass More Asset Management now owns 4,881 shares of the company’s stock worth $271,000 after purchasing an additional 1,057 shares during the last quarter. SRH Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $44,000. Kavar Capital Partners Group LLC increased its position in shares of Novo Nordisk A/S by 0.6% during the third quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after buying an additional 200 shares during the period. Perigon Wealth Management LLC raised its stake in Novo Nordisk A/S by 316.5% during the third quarter. Perigon Wealth Management LLC now owns 48,375 shares of the company’s stock worth $2,684,000 after buying an additional 36,761 shares during the last quarter. Finally, Sapient Capital LLC lifted its holdings in Novo Nordisk A/S by 1.4% in the third quarter. Sapient Capital LLC now owns 18,376 shares of the company’s stock valued at $1,020,000 after buying an additional 262 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.9%

Shares of Novo Nordisk A/S stock opened at $51.40 on Tuesday. The stock has a market capitalization of $229.51 billion, a PE ratio of 14.94 and a beta of 0.67. Novo Nordisk A/S has a 52 week low of $43.08 and a 52 week high of $93.80. The stock has a 50 day moving average price of $49.27 and a two-hundred day moving average price of $56.41. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approved Novo’s oral Wegovy pill, broadening how patients can take its leading GLP?1 weight?loss therapy and opening a large new addressable market for oral treatment forms. Novo Nordisk’s Wegovy Pill Wins U.S. Approval
• Positive Sentiment: Early analyst/coverage pieces highlight strong efficacy data for the oral Wegovy (noted mean weight loss and high share of patients >20% weight loss), positioning the pill as a potential market?share and growth driver versus rivals. Novo Nordisk: Oral Weight-Loss To The Rescue
• Positive Sentiment: Market reaction: some outlets report a strong short?term rally (double?digit intraday moves in recent sessions) after the pill approval, reflecting renewed investor optimism about sales upside. Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK
• Positive Sentiment: Coverage suggests the FDA nod could lift healthcare ETFs and related peers as the oral GLP?1 opportunity reshapes the sector, a tailwind for investor flows into NVO and peers. The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
• Positive Sentiment: Reports say Novo is pricing the oral Wegovy to undercut Eli Lilly in direct?to?consumer channels — a deliberate share?capture strategy that should speed adoption even if it compresses unit economics. With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market
• Neutral Sentiment: Interest/attention indicators: NVO is a trending stock on investor screens — increased search and mention volume can amplify short?term volatility but isn’t a fundamental read. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Competitive landscape: coverage notes heightened rivalry with Eli Lilly (new oral entrants and filings). Competition increases execution risk but also validates a large market. The Weight Loss Drug Competition Is Heating Up
• Negative Sentiment: Pricing pressure in China: Novo has cut Wegovy prices in some Chinese provinces — reports say prices were nearly halved in places as the company preempts generic competition; this raises near?term revenue and margin risk in a large market. Novo cuts Wegovy prices in some Chinese provinces, local media reports Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat

Analyst Ratings Changes

A number of analysts have weighed in on the company. Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 22nd. Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating on the stock. The Goldman Sachs Group reduced their price objective on shares of Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, November 28th. Finally, Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $53.33.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.